The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Patients with cluster headaches present differently depending on whether they have ever been exposed to tobacco.
The United States Cluster Headache Survey assessed tobacco exposure in individuals with cluster headaches.
Clinicians discuss the clinical implications of headache and comorbid sleep disturbances.
Emerging evidence suggests that sphenopalatine ganglion stimulation may be an effective treatment for refractory cluster headache.
In episodic cluster headaches, acute noninvasive vagus nerve stimulation led to significantly higher rates of participants without pain.
A recently published article exposes a gaping hole in the access to an effective first-line therapy for a portion of patients with cluster headache in the United States.
Cluster headaches are considered the most severe headache type and the most difficult to treat. In 2016, the American Headache Society released new evidence-based guidelines for the treatment of cluster headache.
Tobacco use, alcohol consumption, age at disease onset, and sleep quality are predictors of cluster headache severity.
Results of a recent study found that the current costs of medical grade oxygen for use in the treatment of cluster headache are not "prohibitively expensive" for either healthcare insurance providers or for patients.
Local and painful symptoms and signs and general symptoms occur frequently prior to cluster headache attacks.
gammaCore, a hand-held device for treating episodic cluster headaches via mild electrical stimulation of the vagus nerve is now available in the United States.
The FDA has approved the use of gammaCore, the first handheld, non-invasive device to treat pain associated with episodic cluster headaches in adults.
Headaches are a common complaint in primary care, and they are often connected to sleep in a variety of ways.
Treatment of cluster headache by sphenopalatine ganglion stimulation has long-term benefits in the prevention of attacks.
Clinical Pain Advisor Articles
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Remission Rates and Predictors of Chronic Headache
- Overuse and Underuse of Imaging Common in Low Back Pain Management
- Unit-Dose Packaging of Buprenorphine-Naloxone Effective on Unintentional Pediatric Exposure
- Language Used in Medical Record Can Affect Patient Care
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes